Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$22.77

0.66% day before yesterday

NYSE, Dec 27, 10:10 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$22.77

+12.81 128.61% 5Y

NYSE, Closing price Fri, Dec 27 2024

+0.15 0.66%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$25.83b
Enterprise Value	$42.11b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	15.37
EV/Sales (TTM) EV/Sales	2.50
P/S ratio (TTM) P/S ratio	1.54
P/B ratio (TTM) P/B ratio	4.26
Revenue growth (TTM) Revenue growth	9.85%
Revenue (TTM) Revenue	$16.81b
EBIT (operating result TTM) EBIT	$3.77b
Free Cash Flow (TTM) Free Cash Flow	$2.74b
Cash position	$3.32b
EPS (TTM) EPS	$-0.85
P/E forward	525.47
P/S forward	1.57
EV/Sales forward	2.56
Short interest	1.99%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

9x Buy

82%

2x Hold

18%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy

82%

Hold

18%

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	16,814 16,814	10% 10% 100%
- Direct Costs	8,412 8,412	2% 2% 50%
Gross Profit	8,402 8,402	19% 19% 50%
- Selling and Administrative Expenses	2,594 2,594	16% 16% 15%
- Research and Development Expense	978 978	4% 4% 6%
EBITDA	4,830 4,830	25% 25% 29%
- Depreciation and Amortization	1,056 1,056	11% 11% 6%
EBIT (Operating Income) EBIT	3,774 3,774	42% 42% 22%
Net Profit	-959 -959	57% 57% -6%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Positive

Seeking Alpha

●

one day ago

Duvakitug And Teva's Growth: A Game Changer In Pharma

On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis. However, a month and a half before this news, the Israeli pharmaceutical company pleased investors by once again beating analysts' expectations by a wide margin. So, Uzedy's sales amounted to $35 million in the...

Positive

The Motley Fool

●

5 days ago

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025

Over the last two years, there hasn't been a hotter trend on Wall Street than the rise of artificial intelligence (AI). The ability for AI-powered software and systems to become more proficient at their existing tasks, as well as evolve to learn new jobs over time without human intervention, gives this technology a virtually limitless ceiling and broad-based utility in most industries.

Neutral

GlobeNewsWire

●

5 days ago

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Employees	37,226
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now